Long‐term risk of colorectal cancer after screen‐detected adenoma: Experiences from a Danish gFOBT‐positive screening cohort

Bjerrum, Andreas; Lindebjerg, Jan; Andersen, O. Ortved; Fischer, Anders; Lynge, Elsebeth

doi:10.1002/ijc.32850

Cited by 8 publications

(15 citation statements)

References 29 publications

(33 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The initial literature search resulted in 1634 studies. After the selection criteria were applied, 112 studies were selected and reviewed in detail, and 12 studies were included in the final analysis 10,11,[17][18][19][22][23][24][25][26][27][28] (Figure 1). Four studies were from the United States (n ¼199,145), 1 was a multicenter study from Taiwan and China (n ¼ 4483), and 1 study each was from Korea (n ¼ 2452), Israel (n ¼ 728), the United Kingdom (n ¼19,806), France (n ¼5,779), Norway (n¼40,826), Denmark (n ¼ 711), and Poland (n ¼236,089).…”

Section: Resultsmentioning

confidence: 99%

“…All of these studies were population-based cohort studies, of which 4 were prospective, 22,23,25,26 and 7 were multicenter studies. 11,[17][18][19][26][27][28] Only 2 studies 24,25 reported the actual number of colonoscopies performed in each group for the duration of follow-up. An overview of the individual studies with their demographic data is provided in Table 1 and Table 2.…”

Section: Resultsmentioning

confidence: 99%

Section: Standardized Incidence and Mortality Ratios Compared With The General Populationmentioning

confidence: 99%

“…There were 5 studies 10,11,19,27,28 providing data on CRC incidence and mortality between the LRA, HRA groups, and the general population. Bjerrum et al 28 contemporaneous matched general population cohort that did not undergo a screening colonoscopy within 2 years before the study start date. They reported a CRC incidence of 220 per 100,000 person-years in the LRA group, 347 per 100,000 person-years in the HRA group, and 244 per 100,000 person-years in the general population group, with an adjusted hazard ratio of 0.77 (95% CI, 0.25-2.39) for the LRA group and 1.15 (95% CI, 0.74-1.81) for the HRA group compared with the general population.…”

Section: Standardized Incidence and Mortality Ratios Compared With The General Populationmentioning

confidence: 99%

“…They reported a CRC incidence of 220 per 100,000 person-years in the LRA group, 347 per 100,000 person-years in the HRA group, and 244 per 100,000 person-years in the general population group, with an adjusted hazard ratio of 0.77 (95% CI, 0.25-2.39) for the LRA group and 1.15 (95% CI, 0.74-1.81) for the HRA group compared with the general population. 28 The "general population" reported in other studies calculated the expected rates from population statistics. The expected cases of CRC and mortality were calculated in the general population by estimating the number of sex-and 5year age-group-specific person observed-years of CRC and mortality multiplied by the corresponding incidence and mortality in the general population of the national databases of the respective countries.…”

Section: Standardized Incidence and Mortality Ratios Compared With The General Populationmentioning

confidence: 99%

See 4 more Smart Citations

Risk of Colorectal Cancer and Cancer Related Mortality After Detection of Low-risk or High-risk Adenomas, Compared With No Adenoma, at Index Colonoscopy: A Systematic Review and Meta-analysis

et al. 2021

View full text Add to dashboard Cite

BACKGROUND & AIMS:The risk of metachronous colorectal cancer (CRC) among patients with no adenomas, low-risk adenomas (LRAs), or high-risk adenomas (HRAs), detected at index colonoscopy, is unclear. We performed a systematic review and meta-analysis to compare incidence rates of metachronous CRC and CRC-related mortality after a baseline colonoscopy for each group. METHODS: We searched the PubMed, Embase, Google Scholar, and Cochrane databases for studies that reported the incidence of CRC and adenoma characteristics after colonoscopy. The primary outcome was odds of metachronous CRC and CRC-related mortality per 10,000 person-years of follow-up after baseline colonoscopy for all the groups. RE-SULTS: Our final analysis included 12 studies with 510,019 patients (mean age, 59.2 ± 2.6 years; 55% male; mean duration of follow up, 8.5 ± 3.3 years). The incidence of CRC per 10,000 person-years was marginally higher for patients with LRAs compared to those with no adenomas (4.5 vs 3.4; odds ratio [OR], 1.26; 95% CI, 1.06-1.51; I 2 ¼0), but significantly higher for patients with HRAs compared to those with no adenoma ( 13.8 vs 3.4; odds ratio [OR], 2.92; 95% CI, 2.31-3.69; I 2 ¼0 ) and patients with HRAs compared to LRAs (13.81 vs 4.5; OR, 2.35; 95% CI, 1.72-3.20; I 2 ¼55%). However, the CRC-related mortality per 10,000 person-years did not differ significantly for patients with LRAs compared to no adenomas (OR, 1.15; 95% CI, 0.76-1.74; I 2 ¼0) but was significantly higher in persons with HRAs compared with LRAs (OR, 2.48; 95% CI, 1.30-4.75; I 2 ¼38%) and no adenomas (OR, 2.69; 95% CI, 1.87-3.87; I 2 ¼0). CONCLUSIONS: The results of this systematic review and meta-analysis demonstrate that the risk of metachronous CRC and mortality is significantly higher for patients with HRAs, but this risk is very low in patients with LRAs, comparable to patients with no adenomas. Follow-up of patients with LRAs detected at index colonoscopy should be the same as for persons with no adenomas.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Standardized Incidence and Mortality Ratios Compared With The General Populationmentioning

confidence: 99%

Section: Standardized Incidence and Mortality Ratios Compared With The General Populationmentioning

confidence: 99%

Section: Standardized Incidence and Mortality Ratios Compared With The General Populationmentioning

confidence: 99%

See 3 more Smart Citations

Risk of Colorectal Cancer and Cancer Related Mortality After Detection of Low-risk or High-risk Adenomas, Compared With No Adenoma, at Index Colonoscopy: A Systematic Review and Meta-analysis

et al. 2021

View full text Add to dashboard Cite

show abstract

Serum IgG N‐glycans enable early detection and early relapse prediction of colorectal cancer

Duan

Sha

et al. 2022

Intl Journal of Cancer

View full text Add to dashboard Cite

Colorectal cancer (CRC) develops mainly from colorectal advanced adenomas (AA), which are considered precancerous lesions. Novel early diagnostic biomarkers are urgently needed to distinguish CRC and AA from healthy control (HC). Alternative glycosylation of serum IgG has been shown to be closely associated with CRC. We aimed to explore the potential of IgG N‐glycan as biomarkers in the early differential diagnosis of CRC. The study population was strictly matched to the exclusion criteria process. Serum IgG N‐glycan profiles were analyzed by a robust and reliable relative quantitative method based on ultra‐performance liquid chromatography (UPLC). Relative quantification and classification performance of IgG N‐glycans were evaluated by Mann‐Whitney U tests and ROC curve based on directly detected and derived glycan traits, respectively. Six and 14 directly detected glycan traits were significantly changed in AA and CRC, respectively, compared with HC. GP1 and GP3 were able to accurately distinguish AA from HC for early precancerous lesions screening. GP4 and GP14 provided a high value in discriminating CRC from HC. A novel combined index named GlycoF, including GP1, GP3, GP4, GP14 and CEA was developed to provide a potential early diagnostic biomarker in discriminating simultaneously AA (AUC = 0.847) and CRC (AUC = 0.844) from HC. GlycoF also demonstrated a superior CRC detection rate across CRC all stages and conspicuous prediction ability of risk of relapse. Serum IgG N‐glycans analysis provided powerful early screening biomarkers that can efficiently differentiate CRC and AA from HC.

show abstract

Detection of colorectal cancer and advanced neoplasia during first surveillance interval after detection of adenomas in fecal immunochemical test cancer screening: a nationwide study

Larsen,

Jørgensen,

Hagemann-Madsen

et al. 2024

Endoscopy

View full text Add to dashboard Cite

Background Adenoma surveillance guidelines are based on non-fecal immunochemical test (FIT)-based screening settings. However, colorectal cancer (CRC) risk may be different in FIT-positive screening populations. We evaluated the CRC and advanced adenoma risk within the recommended surveillance periods in the Danish FIT-based CRC screening program for participants with intermediate or high risk adenomas according to 2010 European guidelines. Furthermore, we estimated CRC risk for those who were not recommended surveillance according to European Society of Gastrointestinal Endoscopy (ESGE) 2020 guidelines. Methods Using nationwide health registries, we identified 17 936 FIT-screening participants from 2014–2017 with adenomas undergoing surveillance (high risk 1 year, intermediate risk 3 years). Participants with a follow-up examination were included (N = 10 068). Relative risk (RR) of CRC and advance adenoma was compared between intermediate and high risk groups and between intermediates who were recommended surveillance (S) or no surveillance (NS) according to 2020 ESGE guidelines. Results During surveillance, CRC occurred in 0.59% of the high risk group and 1.11% of the intermediate risk group (RR 0.53 [95%CI 0.34–0.84]). The high risk group had a 24% increased risk of advanced adenoma. CRC occurred in 1.69% of the intermediateNS group and 0.87% of the intermediateS group (RR 1.94 [95%CI 1.18–3.21]), and RR for advanced adenoma was 1.19 (95%CI 1.03–1.37). Conclusion CRC detection was lower among participants rated at higher risk at initial CRC screening. Findings at first screen-derived colonoscopy might not be as good a predictor of CRC risk in a FIT-positive screening population.

show abstract

Long‐term risk of colorectal cancer after screen‐detected adenoma: Experiences from a Danish gFOBT‐positive screening cohort

Abstract: This is the author manuscript accepted for publication and has undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as

Cited by 8 publications

References 29 publications

Risk of Colorectal Cancer and Cancer Related Mortality After Detection of Low-risk or High-risk Adenomas, Compared With No Adenoma, at Index Colonoscopy: A Systematic Review and Meta-analysis

Risk of Colorectal Cancer and Cancer Related Mortality After Detection of Low-risk or High-risk Adenomas, Compared With No Adenoma, at Index Colonoscopy: A Systematic Review and Meta-analysis

Serum IgG N‐glycans enable early detection and early relapse prediction of colorectal cancer

Detection of colorectal cancer and advanced neoplasia during first surveillance interval after detection of adenomas in fecal immunochemical test cancer screening: a nationwide study

Contact Info

Product

Resources

About